BACKGROUND: Although pulmonary valve replacement (PVR) is effective in reducing right ventricular (RV) volume overload in patients with chronic pulmonary regurgitation, persistent RV dysfunction and subsequent adverse clinical outcomes have been reported. This trial was conducted to investigate whether the addition of surgical RV remodeling with exclusion of scar tissue to PVR would result in improved RV function and laboratory and clinical parameters, as compared with PVR alone. METHODS AND RESULTS:Between February 2004 and October 2008, 64 patients who underwent RV outflow tract procedures in early childhood had more than or equal to moderate pulmonary regurgitation, and fulfilled defined criteria for PVR were randomly assigned to undergo either PVR alone (n=34) or PVR with surgical RV remodeling (n=30). No significant difference was observed in the primary outcome (change in RV ejection fraction, -2±7% in the PVR alone group and -1±7% in the PVR with RV remodeling group; P=0.38) or in any of the secondary outcomes at 6-month postoperative follow-up. Multivariable analysis of the entire cohort identified preoperative RV end-systolic volume index <90 mL/m(2) and QRS duration <140 ms to be associated with optimal postoperative outcome (normal RV size and function), and RV ejection fraction <45% and QRS duration ≥160 ms to be associated with suboptimal postoperative outcome (RV dilatation and dysfunction). CONCLUSIONS: The addition of surgical remodeling of the RV to PVR in patients with chronic pulmonary regurgitation did not result in a measurable early benefit. Referral to PVR based on QRS duration, RV end-systolic volume, or RV ejection fraction may be beneficial. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00112320.
RCT Entities:
BACKGROUND: Although pulmonary valve replacement (PVR) is effective in reducing right ventricular (RV) volume overload in patients with chronic pulmonary regurgitation, persistent RV dysfunction and subsequent adverse clinical outcomes have been reported. This trial was conducted to investigate whether the addition of surgical RV remodeling with exclusion of scar tissue to PVR would result in improved RV function and laboratory and clinical parameters, as compared with PVR alone. METHODS AND RESULTS: Between February 2004 and October 2008, 64 patients who underwent RV outflow tract procedures in early childhood had more than or equal to moderate pulmonary regurgitation, and fulfilled defined criteria for PVR were randomly assigned to undergo either PVR alone (n=34) or PVR with surgical RV remodeling (n=30). No significant difference was observed in the primary outcome (change in RV ejection fraction, -2±7% in the PVR alone group and -1±7% in the PVR with RV remodeling group; P=0.38) or in any of the secondary outcomes at 6-month postoperative follow-up. Multivariable analysis of the entire cohort identified preoperative RV end-systolic volume index <90 mL/m(2) and QRS duration <140 ms to be associated with optimal postoperative outcome (normal RV size and function), and RV ejection fraction <45% and QRS duration ≥160 ms to be associated with suboptimal postoperative outcome (RV dilatation and dysfunction). CONCLUSIONS: The addition of surgical remodeling of the RV to PVR in patients with chronic pulmonary regurgitation did not result in a measurable early benefit. Referral to PVR based on QRS duration, RV end-systolic volume, or RV ejection fraction may be beneficial. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00112320.
Authors: Tal Geva; Bryan M Sandweiss; Kimberlee Gauvreau; James E Lock; Andrew J Powell Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094
Authors: Alexander van Straten; Hubert W Vliegen; Mark G Hazekamp; Jeroen J Bax; Paul H Schoof; Jaap Ottenkamp; Ernst E van der Wall; Albert de Roos Journal: Radiology Date: 2004-12 Impact factor: 11.105
Authors: P M Pattynama; H J Lamb; E A Van der Velde; R J Van der Geest; E E Van der Wall; A De Roos Journal: Magn Reson Imaging Date: 1995 Impact factor: 2.546
Authors: M A Gatzoulis; S Balaji; S A Webber; S C Siu; J S Hokanson; C Poile; M Rosenthal; M Nakazawa; J H Moller; P C Gillette; G D Webb; A N Redington Journal: Lancet Date: 2000-09-16 Impact factor: 79.321
Authors: Robert H Jones; Eric J Velazquez; Robert E Michler; George Sopko; Jae K Oh; Christopher M O'Connor; James A Hill; Lorenzo Menicanti; Zygmunt Sadowski; Patrice Desvigne-Nickens; Jean-Lucien Rouleau; Kerry L Lee Journal: N Engl J Med Date: 2009-03-29 Impact factor: 91.245
Authors: Hubert W Vliegen; Alexander van Straten; Albert de Roos; Arno A W Roest; Paul H Schoof; Aeilko H Zwinderman; Jaap Ottenkamp; Ernst E van der Wall; Mark G Hazekamp Journal: Circulation Date: 2002-09-24 Impact factor: 29.690
Authors: Timothy Cotts; Paul Khairy; Alexander R Opotowsky; Anitha S John; Anne Marie Valente; Ali N Zaidi; Stephen C Cook; Jamil Aboulhosn; Jennifer Grando Ting; Michelle Gurvitz; Michael J Landzberg; Amy Verstappen; Joseph Kay; Michael Earing; Wayne Franklin; Brian Kogon; Craig S Broberg Journal: Int J Cardiol Date: 2013-12-24 Impact factor: 4.164
Authors: Manar D Samad; Gregory J Wehner; Mohammad R Arbabshirani; Linyuan Jing; Andrew J Powell; Tal Geva; Christopher M Haggerty; Brandon K Fornwalt Journal: Eur Heart J Cardiovasc Imaging Date: 2018-07-01 Impact factor: 6.875
Authors: Scott A Simpson; Suzanne L Field; Meng Xu; Benjamin R Saville; David A Parra; Jonathan H Soslow Journal: Pediatr Cardiol Date: 2017-12-14 Impact factor: 1.655
Authors: Dalin Tang; Heng Zuo; Chun Yang; Zheyang Wu; Xueying Huang; Rahul H Rathod; Alexander Tang; Kristen L Billiar; Tal Geva Journal: Mol Cell Biomech Date: 2017